Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology

The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell haematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma.